EMA Approves BioNTech’s COVID-19 Vaccine Manufacturing Site
EMA has approved the manufacturing of drug product for BioNTech’s COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany.
BioNTech announced on March 26, 2021 that the European Medicines Agency (EMA) has approved the manufacturing of drug product for its COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany.
According to a company press release, EMA has approved the production of the vaccine’s messenger RNA (mRNA) at the Marburg facility, meaning the first batches of the vaccine can be delivered to the company’s partner sites for sterile fill/finish, then distributed to the European Union and other countries. The initial batches manufactured at the Marburg site are set to be delivered during the second half of April 2021.
“A key factor in the expansion of our manufacturing network has been the set-up of this new manufacturing site in Marburg, Germany,” BioNTech said in the press release. “BioNTech plans to be able to produce up to 250 million doses of BNT162b2 in the first half of 2021.”
Source: BioNTech
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
